End Fatigue

Strontium Effective in Treating Postmenopausal Osteoporosis

By both stimulating bone growth while reducing the loss of existing bone material, Strontium ranelate has been shown to be able to cause a net increase in bone formation within the human body.

A 2010 review of two large, double-blind, placebo-controlled trials of 5 years' duration showed that strontium was effective in reducing the risk of fractures in women with postmenopausal osteoporosis. Furthermore, patients who continued taking strontium for 3 years after the 5-year trials ended continued to experience protection against new bone fractures and demonstrated additional increased bone density.

Side effects of consuming strontium were minimal, reported by only small numbers of participants as occasional minor nausea or diarrhoea. Some involved in the longer-tem treatment also reported minor memory loss.

Reference

"Spotlight on strontium ranelate: in postmenopausal osteoporosis." PubMed.gov, PMID: 20809666 [PubMed - indexed for MEDLINE]